Dyne Therapeutics reports positive long-term clinical data for DYNE-251 in Duchenne muscular dystrophy.

From GlobeNewswire: 2025-03-16 19:00:00

Dyne Therapeutics announced positive long-term clinical data for DYNE-251 in Duchenne muscular dystrophy patients, showing functional improvement at a selected dose. The DELIVER trial is fully enrolled, with data planned for late 2025, and a potential Biologics License Application submission for U.S. accelerated approval in early 2026. The treatment has a favorable safety profile, with unprecedented dystrophin expression and significant functional improvements observed, paving the way for potential rapid adoption. The updated assessment includes new functional data and confirms the safety profile of DYNE-251. Key milestones and trial details were also shared at the 2025 MDA Clinical & Scientific Conference.



Read more at GlobeNewswire: Dyne Therapeutics Announces New Long-Term Clinical Data